<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39394593</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China.</ArticleTitle><Pagination><StartPage>1141</StartPage><MedlinePgn>1141</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1141</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-10063-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The essence of this scholarly work was to carefully outline the key factors intensifying the virulence and protracted contagion of COVID-19, particularly among individuals afflicted with hematologic malignancies (HM), in an epoch predominantly governed by the Omicron variant.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adults with HM diagnosed with COVID-19 from November 2022 to February 2023 were monitored in this retrospective study. Patient blood samples yielded biochemical data, and COVID-19 was confirmed through RNA or antigen testing. The factors affecting severity and infection duration were examined using both univariate and multivariate logistic regression analyses. For calculating the overall survival probabilities, the Kaplan-Meier product limit approach was employed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the examined cohort, 133 individuals diagnosed with HM and concomitantly infected with COVID-19 were scrutinized. Of the participants, 29.3% (39 patients) were classified as Severe/Critical, while the other 70.7% (94 patients) were categorized as Non-severe. A significant difference was observed in vaccination status: 61.7% of patients in the Non-severe group had received at least a two-dose vaccine regimen, whereas 61.5% of the Severe/Critical group had either minimal or only one dose of vaccination. The data analysis revealed that elevated C-reactive protein levels (≥ 100 mg/L) significantly raised the risk of severe/critical conditions in HM patients with COVID-19, as determined by advanced multivariate logistic regression. The odds ratio was 3.415 with a 95% confidence interval of 1.294-9.012 (p = 0.013). Patients who continued to have positive nucleic acid tests and ongoing symptoms beyond 30 days were categorized as having a persistent infection, whereas those who achieved infection control within this timeframe were categorized as having infection recovery. Of the HM cohort, 11 did not survive beyond 30 days after diagnosis. The results from a competing risk model revealed that increased interleukin-6 levels (HR: 2.626, 95% CI: 1.361-5.075; p = 0.004) was significantly associated with persistent infection. Conversely, receiving more than two vaccine doses (HR: 0.366, 95% CI: 0.158-0.846; p = 0.019), and having high IgG levels (≥ 1000 mg/dl) (HR: 0.364, 95% CI: 0.167-0.791; p = 0.011), were associated with infection recovery. There was a notable disparity in survival rates between patients with persistent infections and infection recovery, with those in the non-persistent group demonstrating superior survival outcomes (P &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, the study determined that HM patients with COVID-19 and increased C-reactive protein levels had a higher likelihood of severe health outcomes. Persistent infection tended to be more prevalent in those with vaccine dosages (&lt; 2 doses), lower IgG levels, and higher interleukin-6 levels.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ye</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuewu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yile</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xiaolong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xinping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Yanling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Liya</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Gaixiang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chunmei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huafeng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>De</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Xingnong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Juying</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Jiejing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Yinjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wanzhuo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Hongyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China. tonghongyan@zju.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. tonghongyan@zju.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China. tonghongyan@zju.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang University Cancer Center, Hangzhou, People's Republic of China. tonghongyan@zju.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82270146</GrantID><Agency>The National Natural Science Foundation of China grants</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="Y">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hematologic malignancy</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>21</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39394593</ArticleId><ArticleId IdType="pmc">PMC11468290</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-10063-2</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-10063-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bronstein Y, Levi S, Herishanu Y. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge. Br J Haematol. 2023;201(6):1125–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">37042235</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemann CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, Brieghel C. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era. Blood. 2022;140(5):445–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9122776</ArticleId><ArticleId IdType="pubmed">35588468</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohn M, Alsuliman T, Lamure S, Cheminant M, Delage J, Merle De Boever C, Tudesq JJ, Marjanovic Z, Van de Wyngaert Z, Malard F, et al. Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak. Leuk Lymphoma. 2022;63(11):2686–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">35719107</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali EAH, Khamees I, Alshurafa A, Qasim H, Abu-Tineh MA, Ahmed K, Saad E, Yassin M. Severe Acute Respiratory Syndrome Coronavirus 2 Omicron variant in patients with Philadelphia-negative myeloproliferative neoplasm: a single Center experience. Oncology. 2022;100(8):460–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35882185</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, Xiang H, Gale RP, Chen S, Qu J, Guo H, Li Q, Zhang Y, Li W. SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia. J Cancer Res Clin Oncol. 2023;149(13):11025–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">37337067</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano L, Salmanton-Garcia J, Marchesi F, Blennow O, Gomes da Silva M, Glenthoj A, van Doesum J, Bilgin YM, Lopez-Garcia A, Itri F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9492383</ArticleId><ArticleId IdType="pubmed">36126318</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuva H, Zhou M, Brau N, Brown ST, Mundi P, Rosenberg TM, Luhrs C, Bates SE, Park YA, Fojo T. Influence of Cancer on COVID-19 incidence, outcomes, and Vaccine Effectiveness: a prospective cohort study of U.S. Veterans. Semin Oncol. 2022;49(5):363–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9353607</ArticleId><ArticleId IdType="pubmed">36055952</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair MJ, Mitterer M, Gattinger P, Berger JM, Trutschnig W, Bathke AC, Gansterer M, Berghoff AS, Laengle S, Gottmann L, et al. Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron. Cancer Cell. 2022;40(5):444–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9001251</ArticleId><ArticleId IdType="pubmed">35429443</ArticleId></ArticleIdList></Reference><Reference><Citation>Taenaka R, Obara T, Kohno K, Aoki K, Ogawa R. Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies. Ann Hematol. 2022;101(8):1877–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989258</ArticleId><ArticleId IdType="pubmed">35391563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbit J, Detroit M, Meyer A, Decroocq J, Deau-Fischer B, Deschamps P, Birsen R, Mondesir J, Franchi P, Miekoutima E et al. Patients with Hematological Malignancies Treated with T-Cell or B-Cell immunotherapy remain at high risk of severe forms of COVID-19 in the Omicron era. Viruses 2022, 14(11).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9696091</ArticleId><ArticleId IdType="pubmed">36366475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo C, Masina L, Pagani C, Cancelli V, Daffini R, Tucci A, Rossi G. High mortality in fully vaccinated hematologic patients treated with anti-CD20 antibodies during the Omicron wave of COVID-19 pandemic. Hematol Oncol. 2023;41(1):205–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539356</ArticleId><ArticleId IdType="pubmed">35933702</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Koff JL, Lai L, Orellana-Noia VM, Surati M, Leal AMK, Ellis ML, Wali B, Moreno A, Linderman SL, et al. Low neutralizing activity of AZD7442 against current SARS-CoV-2 omicron variants in patients with B-cell malignancies. Blood Adv. 2023;7(11):2459–62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906471</ArticleId><ArticleId IdType="pubmed">36622349</ArticleId></ArticleIdList></Reference><Reference><Citation>Avigan ZM, Paredes R, Boussi LS, Lam BD, Shea ME, Weinstock MJ, Peters MLB. Updated COVID-19 clearance time among patients with cancer in the Delta and Omicron waves. Cancer Med. 2023;12(16):16869–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10501268</ArticleId><ArticleId IdType="pubmed">37392171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, West S, Smith K, Barwood J, Kaczmarek E, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8(6):e389–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055205</ArticleId><ArticleId IdType="pubmed">33887255</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180672</ArticleId><ArticleId IdType="pubmed">32332856</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426107</ArticleId><ArticleId IdType="pubmed">32798473</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi J. Prolonged SARS-CoV-2 infection in a CAR T-Cell therapy recipient. JAMA. 2021;325(10):924.</Citation><ArticleIdList><ArticleId IdType="pubmed">33687450</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Chen Y, Tang X. Guidelines for the diagnosis and treatment of coronavirus disease 2019 (COVID-19) in China. Global Health Med. 2020;2(2):66–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731342</ArticleId><ArticleId IdType="pubmed">33330780</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, editors. Jr. : Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395(10241):1907–1918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255743</ArticleId><ArticleId IdType="pubmed">32473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Jemaa AB, Oueslati R, Guissouma J, Ghadhoune H, Ali HB, Allouche H, Trabelsi I, Samet M, Brahmi H. Differences in leucocytes and inflammation-based indices among critically ill patients owing to SARS-CoV-2 variants during several successive waves of COVID-19 pandemic. Int Immunopharmacol 2023;124(Pt A):110836.</Citation><ArticleIdList><ArticleId IdType="pubmed">37633238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Choy KW, Lim HY, Ho P. Laboratory markers of severity across three COVID-19 outbreaks in Australia: has Omicron and vaccinations changed disease presentation? Intern Emerg Med. 2023;18(1):43–52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9472718</ArticleId><ArticleId IdType="pubmed">36103084</ArticleId></ArticleIdList></Reference><Reference><Citation>Heydarifard Z, Shafiei-Jandaghi NZ, Safaei M, Tavakoli F, Shatizadeh Malekshahi S. Comparison of clinical outcomes, demographic, and laboratory characteristics of hospitalized COVID-19 patients during major three waves driven by Alpha, Delta, and Omicron variants in Tehran, Iran. Influenza Other Respir Viruses. 2023;17(8):e13184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10410233</ArticleId><ArticleId IdType="pubmed">37565071</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhang Q, Xu C, Zhang Y, Lu Y, Ai M, Tan X. Differences in clinical characteristics and liver injury between patients diagnosed with the Omicron subvariant BA.5.2 and the prototype of SARS-CoV-2: a single center retrospective study. BMC Gastroenterol. 2023;23(1):271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10408107</ArticleId><ArticleId IdType="pubmed">37553605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, He L, Guo Y, Wang N. Risk factors and drug efficacy for severe illness in hemodialysis patients infected with the Omicron variant of COVID-19. Kidney Blood Press Res. 2023;48(1):642–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10614566</ArticleId><ArticleId IdType="pubmed">37751729</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng L, Chang W. The investigation of kidney involvement in 430 hospitalized patients with Omicron COVID-19 in Tianjin, China. Blood Purif. 2023;52(5):437–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9893007</ArticleId><ArticleId IdType="pubmed">36657422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Yu Y, Hubert SM, Zhang Y, Lu J, Liu S, Xie F, Zhao L, Lei X, Deng W, et al. Prognostic value of pro-inflammatory neutrophils and C-Reactive protein in Cancer Patient with Coronavirus Disease 2019: a Multi-center, Retrospective Study. Front Pharmacol. 2020;11:576994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7656194</ArticleId><ArticleId IdType="pubmed">33192519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng SC, Scicluna BP, Arts RJ, Gresnigt MS, Lachmandas E, Giamarellos-Bourboulis EJ, Kox M, Manjeri GR, Wagenaars JA, Cremer OL, et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol. 2016;17(4):406–13.</Citation><ArticleIdList><ArticleId IdType="pubmed">26950237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Correction to: clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(6):1294–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7131986</ArticleId><ArticleId IdType="pubmed">32253449</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, Burger JA, et al. Antibody response in immunocompromised patients with hematologic cancers who received a 3-Dose mRNA-1273 vaccination schedule for COVID-19. JAMA Oncol. 2022;8(10):1477–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9372904</ArticleId><ArticleId IdType="pubmed">35951338</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman RS, Bhagwan Barge V, Anil Kumar D, Dandu H, Rakesh Kartha R, Bafna V, Aravinda VT, Raghuram TC. A phase II safety and efficacy study on prognosis of moderate pneumonia in Coronavirus Disease 2019 patients with regular intravenous immunoglobulin therapy. J Infect Dis. 2021;223(9):1538–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928808</ArticleId><ArticleId IdType="pubmed">33585890</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw B, Shortt J, Low M, Rogers B, Kaplan Z, Fedele P, Gregory G, Vilcassim S, Gilbertson M, Grigoriadis G, et al. Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2. Intern Med J. 2022;52(12):2172–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">36436197</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, et al. Coronavirus Disease 2019 outcomes, patient vaccination status, and Cancer-related delays during the Omicron Wave: a brief report from the TERAVOLT Analysis. JTO Clin Res Rep. 2022;3(8):100335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9119707</ArticleId><ArticleId IdType="pubmed">35619644</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato DJ, Aguilar-Company J, Ferrante D, Hanbury G, Bower M, Salazar R, Mirallas O, Sureda A, Plaja A, Cucurull M, et al. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncol. 2022;23(7):865–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9162476</ArticleId><ArticleId IdType="pubmed">35660139</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinana JL, Lopez-Corral L, Martino R, Vazquez L, Perez A, Martin-Martin G, Gago B, Sanz-Linares G, Sanchez-Salinas A, Villalon L, et al. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. J Hematol Oncol. 2022;15(1):54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9077637</ArticleId><ArticleId IdType="pubmed">35526045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien KS, Peterson CB, Young E, Chihara D, Manasanch EE, Ramdial JL, Thompson PA. Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. Blood Adv. 2023;7(19):5691–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9896882</ArticleId><ArticleId IdType="pubmed">36696472</ArticleId></ArticleIdList></Reference><Reference><Citation>Azar JH, Evans JP, Sikorski MH, Chakravarthy KB, McKenney S, Carmody I, Zeng C, Teodorescu R, Song NJ, Hamon JL et al. Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. JCI Insight 2023, 8(6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10070099</ArticleId><ArticleId IdType="pubmed">36749632</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Akhtar A, Linderman SL, Lai L, Orellana-Noia VM, Valanparambil R, Ahmed H, Zarnitsyna VI, McCook-Veal AA, Switchenko JM, et al. Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with Non-hodgkin Lymphoma and chronic lymphocytic leukemia. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40(26):3020–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470134</ArticleId><ArticleId IdType="pubmed">35436146</ArticleId></ArticleIdList></Reference><Reference><Citation>Krekeler C, Reitnauer L, Bacher U, Khandanpour C, Steger L, Boeckel GR, Klosner J, Tepasse PR, Kemper M, Hennies MT et al. Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario. Cancers 2022, 14(22).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9688056</ArticleId><ArticleId IdType="pubmed">36428605</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow O, Salmanton-Garcia J, Nowak P, Itri F, Van Doesum J, Lopez-Garcia A, Farina F, Jaksic O, Pinczes LI, Bilgin YM, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report. Am J Hematol. 2022;97(8):E312–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349555</ArticleId><ArticleId IdType="pubmed">35702878</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Lin Y, Li Y, Chen S, Zhou L, Song H, Yang C, Zhang H, Zhou J, Sun S, et al. Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine. Cell. 2023;186(21):4615–e46314616.</Citation><ArticleIdList><ArticleId IdType="pubmed">37769658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>